Where are legislative trends pointing on biopharmaceutical patents? Sona De, a partner at Sidley, reviews existing proposals ...
Local market pharmacovigilance (PV) requirements can be daunting to manage successfully. Experts at PharmaLex provide best ...
The FDA’s Rare Pediatric Disease Priority Review Voucher (PRV) program is set to expire on December 20, 2024, if the U.S.
Make America Healthy Again” is coming to Washington. Jennifer D. Newberger and Jeffrey N. Gibbs at Hyman, Phelps, & McNamara, ...
Sanofi’s chief learning officer Wanda Shoer explains the importance of self-awareness about of your own core skills, talents, ...
Everyone in the business is looking for breakthroughs, but only a select few win breakthrough therapy designation from the FDA. Under the guidance of Ira Gupta, M.D. and Shanthi Ganeshan, Ph.D, GSK ...
This past spring, Xaira Therapeutics launched with $1 billion in backing, a who's-who mashup of Silicon Valley and biopharma stars led by Marc Tessier-Lavigne in the C-suite, and a mission to develop ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback